Clinical Trial

Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)

Study acronym: Spectrum
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 11, 2026 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
1\. To assess treatment efficacy with YCJ-01 by changes in the number of epileptic seizures in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex. 2. To assess the safety of the treatment with YCJ-01 in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex.
Trial Details
NCT Number NCT07403266
Lead Sponsor Oils4Cure
Conditions Tuberous Sclerosis Complex (TSC)
Enrollment 84 participants
Start Date 2024-06-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-02-11